Krystal Biotech (KRYS) Cash from Operations (2016 - 2026)

Krystal Biotech (KRYS) has 11 years of Cash from Operations data on file, last reported at 80382000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Operations rose 159.56% year-over-year to 80382000.0; the trailing twelve-month figure through Mar 2026 stood at 250278000.0 (up 80.7% YoY), and the FY2025 full-year result was 200865000.0, up 62.75% from the prior year.
• Cash from Operations grew to 80382000.0 in Q1 2026, from 77508000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 80382000.0 in Q1 2026 to a low of 43059000.0 in Q2 2022.
• A 5-year average of 12664352.94 and a median of 4168000.0 in 2024 frame the typical range for Cash from Operations.
• Across the five-year window, Cash from Operations sank 325.11% in 2022 and surged 1365.09% in 2025, its largest moves.
• Tracing KRYS's Cash from Operations over 5 years: stood at 22329000.0 in 2022, then jumped by 67.61% to 7232000.0 in 2023, then jumped by 830.68% to 52843000.0 in 2024, then surged by 46.68% to 77508000.0 in 2025, then gained by 3.71% to 80382000.0 in 2026.
• Business Quant data shows KRYS's Cash from Operations at 80382000.0 in Q1 2026, 77508000.0 in Q4 2025, and 39659000.0 in Q3 2025.